Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic ...

Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...

Future Market Insights (FMI), a premier market research and consulting firm, today announced the publication of its latest ...

Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE ...

Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell ...

But according to wellness expert and Dietium.com founder Srasti, our collective reliance on this single number is “not just ...

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Early improvements in skin clearance were observed, with significant differences in vIGA-AD response rates as early as week 1 and maintained through week 8 in children with or without atopic ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

In a study published in Analytical Chemistry, a research team led by Wang Junfeng from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a novel immobilization ...

This article explores how advances in automation, 3D cell models and AI are transforming high-throughput screening, driving ...